Response to immunotherapy in a patient with Landau‐Kleffner syndrome and GRIN2A mutation
Citations Over TimeTop 19% of 2016 papers
Abstract
Landau-Kleffner syndrome (LKS) has been demonstrated in the past to respond to immunotherapy. Recently, some cases of LKS have been shown to be secondary to glutamate receptor (GRIN2A) mutations. Whether such cases respond to immunotherapy is not known. Here, we present the case of a 3-year-old boy with LKS found to have a GRIN2A heterozygous missense mutation, whose clinical symptoms and EEG responded to a course of combination oral steroids and monthly infusions of intravenous immunoglobulin. He then relapsed after discontinuation of this therapy, and responded again after a second course of intravenous immunoglobulin. We conclude that immunotherapy should be considered as a therapeutic option in patients with LKS who are also found to harbour GRIN2A mutations.
Related Papers
- Current and future applications of SPECT in clinical psychiatry.(1992)
- [Discontinuation of chronic treatment with lithium salts].(1992)
- Types Research of Discontinuation of a Crime(2007)
- → Accurate collection of reasons for treatment discontinuation to better define estimands in clinical trials(2022)